Europe greenlights first human genetic modifications

In a European first, Crispr Therapeutics (CRISPR is a gene editing technology) will begin human trials of a gene-splicing treatment for beta thalassaemia, a blood disorder that reduces the production of haemoglobin, which carries oxygen to cells.

This article is exclusive to Biznews Premium. Members please login here. Not yet subscribed? Taste before you eat by signing up here for free 30 day trial (card details required; WSJ access only available to paying members)